Literature DB >> 7998774

Complex I, iron, and ferritin in Parkinson's disease substantia nigra.

V M Mann1, J M Cooper, S E Daniel, K Srai, P Jenner, C D Marsden, A H Schapira.   

Abstract

Elevated iron levels, enhanced oxidative damage, and complex I deficiency have been identified in the substantia nigra of Parkinson's disease patients. To understand the interrelationship of these abnormalities, we analyzed iron levels, ferritin levels, and complex I activity in the substantia nigra of patients with Parkinson's disease. Total iron levels were increased significantly, ferritin levels were unchanged, and complex I activities were decreased significantly in the substantia nigra samples. The failure of ferritin levels to increase with elevated iron concentrations suggests that the amount of reactive iron may increase in the substantia nigra of Parkinson's disease patients. There was no correlation between the iron levels and complex I activity or the iron-ferritin ratio and complex I activity in the substantia nigra samples.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7998774     DOI: 10.1002/ana.410360612

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  67 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

2.  Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.

Authors:  R Lee Mosley; Eric J Benner; Irena Kadiu; Mark Thomas; Michael D Boska; Khader Hasan; Chad Laurie; Howard E Gendelman
Journal:  Clin Neurosci Res       Date:  2006-12-06

Review 3.  The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease.

Authors:  D J Surmeier; J N Guzman; J Sanchez-Padilla; P T Schumacker
Journal:  Neuroscience       Date:  2011-08-25       Impact factor: 3.590

Review 4.  The role of iron in brain ageing and neurodegenerative disorders.

Authors:  Roberta J Ward; Fabio A Zucca; Jeff H Duyn; Robert R Crichton; Luigi Zecca
Journal:  Lancet Neurol       Date:  2014-10       Impact factor: 44.182

5.  Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson's disease brains.

Authors:  Rajeswara Babu Mythri; C Venkateshappa; G Harish; Anita Mahadevan; Uday B Muthane; T C Yasha; M M Srinivas Bharath; S K Shankar
Journal:  Neurochem Res       Date:  2011-04-12       Impact factor: 3.996

Review 6.  Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease.

Authors:  D James Surmeier; Jaime N Guzman; Javier Sanchez-Padilla
Journal:  Cell Calcium       Date:  2010-01-06       Impact factor: 6.817

Review 7.  The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start?

Authors:  Junghee Lee; Jung Hyun Boo; Hoon Ryu
Journal:  Adv Drug Deliv Rev       Date:  2009-08-27       Impact factor: 15.470

8.  Trichloroethylene induces dopaminergic neurodegeneration in Fisher 344 rats.

Authors:  Mei Liu; Dong-Young Choi; Randy L Hunter; Jignesh D Pandya; Wayne A Cass; Patrick G Sullivan; Hyoung-Chun Kim; Don M Gash; Guoying Bing
Journal:  J Neurochem       Date:  2009-11-17       Impact factor: 5.372

Review 9.  Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review.

Authors:  Sarah Jesse; Petra Steinacker; Stefan Lehnert; Frank Gillardon; Bastian Hengerer; Markus Otto
Journal:  CNS Neurosci Ther       Date:  2009-03-09       Impact factor: 5.243

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.